Light & Recovery
Laukkanen JAMA Sauna Study: CVD and Sudden Cardiac Death in Finnish Men
KIHD 2,315 men, ~20.7-year follow-up: 4–7 saunas/week vs 1× associated with HR 0.37 SCD and 0.50 fatal CVD after adjustment—graded dose-response, not proven causation.
KIHD/Laukkanen 2015: men saunaing 4–7×/week vs 1× had ~63% lower SCD hazard and ~50% lower fatal CVD hazard after adjustment. Landmark observational dose-response—not infrared RCT proof.
If you have seen a sauna longevity chart online, it almost always descends from Eastern Finland’s KIHD men. Read the design before buying a cabin.
This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.
What was the study design?
Prospective KIHD cohort: 2,315 men age 42–60; baseline 1984–1989; median follow-up 20.7 years.
Events: 190 SCD; 281 fatal CHD; 407 fatal CVD; 929 all-cause deaths.
Frequency strata: 1×/wk n=601; 2–3× n=1,513; 4–7× n=201.
What hazard ratios define the headline?
SCD 4–7 vs 1×: HR 0.37 (0.18–0.75), P trend 0.005.
Fatal CVD 4–7 vs 1×: HR 0.50; fatal CHD HR 0.52; all-cause HR 0.60 class (Mayo summaries of same paper).
Duration >19 vs <11 min: SCD HR 0.48 with significant trend.
| Frequency | SCD HR vs 1× | Notes |
|---|---|---|
| 2–3×/week | 0.78 (NS CI) | Mid stratum |
| 4–7×/week | 0.37 | Headline SCD |
| Fatal CVD 4–7× | 0.50 | Adjusted |
| All-cause 4–7× | 0.60 | Adjusted |
| >19 min sessions | SCD 0.48 vs <11 | Duration signal |
What crude rates illustrate the gradient?
SCD cumulative: 10.1% (1×) vs 7.8% (2–3×) vs 5.0% (4–7×).
All-cause: 49.1% vs 37.8% vs 30.8% over long follow-up.
Crude rates ≠ adjusted causal effects—but they show ordering.
What must readers not overclaim?
Causation; generalizability to infrared; safety of alcohol-plus-sauna; applicability to women from this male-only paper alone (see mixed-sex extensions separately).
Sources: Laukkanen et al. 2015 JAMA IM; JAMA IM full article; Mayo Clin Proc 2018 sauna review.
Readers should dual-source primary literature, translate slogans into exposure units and effect sizes, and rank interventions by expected value under uncertainty. Cheap reversible steps often outrank extreme protocols. Opportunity cost is real: hours spent on unvalidated tests are hours not spent on sleep, training, protein adequacy, and primary care. Sex, life stage, comorbidities, medications, and geography change interpretation. Prefer falsifiable claims with named endpoints over multi-disease cure lists. Update beliefs when stronger trials appear rather than freezing identity around a single paper or influencer narrative. Measured curiosity beats both panic and complacency. Further reading should prioritize primary sources and consensus documents over secondary social summaries. When evidence is mixed, state both the signal and the limits in the same paragraph. When evidence is strong, still avoid overclaiming universality across populations.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.
Sources & citations
Frequently asked